European Union announces new programme to improve Parkinson’s diagnosis

News

Author: Parkinson's Life editorsPublished: 17 January 2018

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

PD-Podcast-DBS

The European Union has announced the launch of the Magnetic Diagnostic Assay for Neurodegenerative Diseases (MADIA) – a project with the ultimate goal of improving diagnosis for those living with Parkinson’s and Alzheimer’s.

The project, which is in partnership with a range of international universities and institutions, will focus on the development of a novel device that will help clinicians perform a simple click and analysis to diagnose both conditions.

Dr Francisco Campos, of the Clinical Neurosciences Research Laboratory, said: “An early diagnosis is crucial to maximise the effectiveness of the treatments in order to mitigate the devastating effects of these illnesses and slow disease progression.

“MADIA is funded by the European Union’s Horizon 2020 research and innovation programme, and consists of a multitasking team with more than 50 professionals in the fields of biology, physics and engineering.”

For comprehensive information about Parkinson’s diagnosis please visit the EPDA website.

Go Back

Share this story

Comments


Related articles


John McLean Studio Lead

Perspectives

Painter with Parkinson’s: John McLean shares some of his favourite works

From large stained-glass windows to abstract explosions of colour

READ MORE
Campaigners win petition for ‘student carer’ tick box on uni application forms

Carers' Corner

Campaigners win petition for ‘student carer’ status on uni application forms

Student carers soon to be recognised on application forms

READ MORE
FDA medication

Advances

When will new Parkinson’s psychosis drug be approved outside of the US?

FDA approves drug to treat hallucinations and delusions

READ MORE